Polymyositis, Dermatomyositis, and Inclusion Body Myositis

Muscle Disease: Pathology and Genetics: Second Edition

Volumn , Issue , 2013, Pages 298-312

  Holton, Janice L ^a   Wedderburn, Lucy R ^b   Hanna, Michael G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016857981     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118635469.ch33     Document Type: Chapter

References (75)

1. Hilton-Jones D. Observations on the classification of the inflammatory myopathies. Presse Med 2011; 40 (4 Pt 2): e199-208.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8): 403-7.
3. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (7): 344-7.
4. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC International Workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14 (5): 337-45.
5. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38 (5): 705-13.
6. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010; 20 (2): 142-7.
7. Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 2010; 20 (6): 414-21.
8. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol 2011; 23 (6): 595-604.
9. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 2011; 11 (1): 6-13.
10. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132 (Pt 6): 1536-44.
11. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003; 27 (4): 407-25.
12. Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011; 7 (11): 664-75.
13. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362 (9388): 971-82.
14. Mastaglia FL. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. Acta Myol 2009; 28 (2): 66-71.
15. Dimachkie MM. Idiopathic inflammatory myopathies. J Neuroimmunol 2011; 231 (1-2): 32-42.
16. Curiel RV, Jones R, Brindle K. Magnetic resonance imaging of the idiopathic inflammatory myopathies: structural and clinical aspects. Ann NY Acad Sci 2009; 1154: 101-14.
17. Maillard SM, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004; 43 (5): 603-8.
18. Wedderburn LR, Varsani H, Li CK, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007; 57 (7): 1192-201.
19. Van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61 (3): 316-21.
20. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70 (6): 418-24.
21. Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am 2011; 37 (2): 143-58, v.
22. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65 (11): 1782-7.
23. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007; 35 (1): 17-23.
24. Van der Pas J, Hengstman GJ, ter Laak HJ, Borm GF, van Engelen BG. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 2004; 75 (1): 136-9.
25. Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001; 159 (4): 1263-73.
26. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol 2011; 7 (5): 297-306.
27. Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996; 97 (12): 2905-10.
28. Benveniste O, Herson S, Salomon B, et al. Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann Neurol 2004; 56 (6): 867-72.
29. Salajegheh M, Pinkus JL, Amato AA, et al. Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 2010; 42 (4): 576-83.
30. Selva-O'Callaghan A, Trallero-Araguas E, Grau-Junyent JM, Labrador-Horrillo M. Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 2010; 22 (6): 627-32.
31. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/betamediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57 (5): 664-78.
32. Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004; 31 (3): 605-9.
33. De Visser M, Emslie-Smith AM, Engel AG. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci 1989; 94 (1-3): 181-92.
34. Pestronk A, Schmidt RE, Choksi R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 2010; 42 (1): 53-61.
35. Bronner IM, Hoogendijk JE, Veldman H, et al. Tubuloreticular structures in different types of myositis: implications for pathogenesis. Ultrastruct Pathol 2008; 32 (4): 123-6.
36. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009; 60 (12): 3784-93.
37. Lopez de Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009; 60 (4): 1160-72.
38. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005; 52 (6): 1824-35.
39. Sato JO, Sallum AM, Ferriani VP, et al. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 2009; 27 (6): 1031-8.
40. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther 2011; 13 (2): 209.
41. Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 2010; 22 (6): 639-43.
42. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007; 157 (4): 637-44.
43. Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971; 25 (3): 240-8.
44. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009; 80 (11): 1186-93.
45. Temiz P, Weihl CC, Pestronk A. Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci 2009; 278 (1-2): 25-9.
46. Nogalska A, Terracciano C, d'Agostino C, King Engel W, Askanas V. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009; 118 (3): 407-13.
47. Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multiprotein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009; 19 (3): 493-506.
48. Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010; 12 (3): 221-8.
49. Pluk H, van Hoeve BJA, van Dooren SHJ. et al. Autoantibodies to cytosolic 5'-nucleotidase IA in inclusion body myositis. Ann Neurol in press.
50. Weihl CC, Pestronk A. Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr Opin Neurol 2010; 23 (5): 482-8.
51. Lunemann JD, Schmidt J, Dalakas MC, Munz C. Macroautophagy as a pathomechanism in sporadic inclusion body myositis. Autophagy 2007; 3 (4): 384-6.
52. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9 (10): 995-1007.
53. Olive M, Janue A, Moreno D, Gamez J, Torrejon-Escribano B, Ferrer I. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009; 68 (3): 262-73.
54. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40 (1): 19-31.
55. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79 (10): 1186-9.
56. Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006; 34 (4): 406-16.
57. Varadhachary AS, Weihl CC, Pestronk A. Mitochondrial pathology in immune and inflammatory myopathies. Curr Opin Rheumatol 2010; 22 (6): 651-7.
58. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201 (4): 591-601.
59. Wedderburn LR, McHugh NJ, Chinoy H, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007; 46 (12): 1786-91.
60. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcriptional intermediary factor 1 family proteins. Arthritis Rheum 2012; 64 (2): 513-22.
61. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56 (9): 3132-7.
62. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011 Jul; 65 (1): 25-34.
63. Chinoy H, Lamb JA, Ollier WE, Cooper RG. An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond. Curr Opin Rheumatol 2009; 21 (6): 588-93.
64. Miller FW, Cooper RG, Vencovsky J, et al. Genome-wide association study of dermatomyositis reveals shared genetic risk factors with other autoimmune diseases. Arthritis Rheum US 2011; 63 (10): S656.
65. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79 (9): 1056-60.
66. Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families. Brain 1997; 12 (Pt 4): 653-61.
67. Confalonieri P, Oliva L, Andreetta F, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003; 142 (1-2): 130-6.
68. Darin N, Kroksmark AK, Ahlander AC, Moslemi AR, Oldfors A, Tulinius M. Inflammation and response to steroid treatment in limbgirdle muscular dystrophy 2I. Eur J Paediatr Neurol 2007; 11 (6): 353-7.
69. Matthews E, Miller JA, MacLeod MR, et al. Sodium and chloride channelopathies with myositis: coincidence or connection? Muscle Nerve 2011; 44 (2): 283-8.
70. Broccolini A, Gidaro T, Morosetti R, Sancricca C, Mirabella M. Hereditary inclusion-body myopathy with sparing of the quadriceps: the many tiles of an incomplete puzzle. Acta Myol 2011; 30 (2): 91-5.
71. Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscul Disord 2009; 19 (5): 308-15.
72. Katsumata Y, Ascherman DP. Animal models in myositis. Curr Opin Rheumatol 2008; 20 (6): 681-5.
73. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 2000; 97 (16): 9209-14.
74. Li CK, Knopp P, Moncrieffe H, et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol 2009; 175 (3): 1030-40.
75. Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet 2010; 19 (9): 1741-55.